[Edaily Starin Gim Ga Yeong Reporter] Japanese actor Kentarō Sakaguchi has announced his marriage. Photo courtesy of Coupang Play
On the 6th, Kentaro Sakaguchi announced on his paid fan club website that he had married a non-celebrity woman he had been dating. He stated, “I have married the woman I am currently dating,” adding, “I will continue to dedicate myself to my career as an actor.” Specific details, such as his wife’s occupation and age, were not disclosed. Kentaro Sakaguchi was embroiled in controversy last year over allegations of cheating. At the time, the local weekly magazine *Shukan Bunshun* reported that while he was living with Ms. A—a hair and makeup artist three years his senior—he was also maintaining a close relationship with fellow actress Mei Nagano. According to the report, Nagano Mei was seen holding hands with Kentarō Sakaguchi on a date and said, “We’re going to get married, so it’s okay if people find out.” Ms. A, upon learning of their relationship, even called Nagano Mei directly to warn her. Later, Nagano Mei was also embroiled in rumors of an affair with actor Kei Tanaka, who is 15 years her senior. Meanwhile, Kentarō Sakaguchi debuted as an exclusive model for *Men’s Non-No* in 2010 and has gained widespread popularity through works such as *Kounodori*, *Let’s Print a Second Edition!*, *Tokyo Tarareba Girls*, *Signal: Long-Unsolved Cases Investigation Unit*, and *And We Go On*. He is well-known in South Korea for his resemblance to Korean actor Seo Kang-joon and has also connected with Korean viewers through the Coupang Play series “What Comes After Love.” He will appear in “Kidnap Game,” set to premiere this October on Channel A and Disney+.
On the sixth anniversary of the passing of the late Lee Kun-Hee, former chairman of SamsungElectronics, Jay Y. Lee and executives from major affiliate companies gathered at the family cemetery in Suwo…
Aptabio Therapeutics Inc.(293780)has expressed confidence ahead of the announcement of the efficacy of its kidney disease treatment candidate “Isuzinaxib” (APX-115). This follows the company’s selecti…
#Orum Therapeutics, Inc. has reappointed a U.S. business development (BD) expert to its board of directors and expanded the limit on stock options granted to U.S. employees. At an investor briefing he…